Alector Inc News Today

Alector, Inc. (NASDAQ:ALEC – Get Free Report) CEO Arnon Rosenthal sold 25,135 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $4.80, for a total value of $120,648.00. Following the completion of the sale, the chief executive officer now owns 1,975,245 shares […]

Shares of Alector, Inc. (NASDAQ:ALEC – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seven brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the […]

Shares of Alector, Inc. (NASDAQ:ALEC – Get Free Report) have received an average recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the […]

Euclidean Capital LLC lifted its stake in shares of Alector, Inc. (NASDAQ:ALEC – Free Report) by 33.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,307,858 shares of the company’s stock after purchasing an additional 326,964 shares during the period. Alector comprises about 1.8% of […]

Hsbc Holdings PLC grew its position in Alector, Inc. (NASDAQ:ALEC – Free Report) by 64.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,807 shares of the company’s stock after buying an additional 14,472 shares during the quarter. Hsbc Holdings PLC’s holdings in […]

Acadian Asset Management LLC increased its holdings in shares of Alector, Inc. (NASDAQ:ALEC – Free Report) by 68.2% in the third quarter, Holdings Channel.com reports. The fund owned 153,266 shares of the company’s stock after buying an additional 62,155 shares during the quarter. Acadian Asset Management LLC’s holdings in Alector were worth $993,000 at the […]

Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer’s disease (AD), expected in Q4 2024; trial enrollment completed in Q3 2023

SOUTH SAN FRANCISCO, Calif. — SOUTH SAN FRANCISCO, Calif. — Alector Inc. on Tuesday reported a loss of $41.4 million in its fourth quarter. On a per-share basis, the South San Francisco,...

The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globallySOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 -- Alector, Inc. and GSK plc today...

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GSK plc (LSE/NYSE: GSK) today announced that the...